

International Patent Class (Main): A61K-037/54; A61K-047/28
International Patent Class (Additional): A23L-001/03

009934327

WPI Acc No: 1994-202039/199425

Orally administered therapeutic protein compsn. - comprises combination of protein and stabilising agent in aq. soln. to form microcapsules.

Patent Assignee: UNIV CINCINNATI (UYCI-N)

Inventor: LITWIN A; MICHAEL J G; MICHAEL J; GABRIEL M J; GABRIEL M

Number of Countries: 023 Number of Patents: 013

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
EP 603992	A1	19940629	EP 93300005	A	19930104	199425 B
AU 9331045	A	19940707	AU 9331045	A	19930105	199431
CA 2086631	A	19940623	CA 2086631	A	19930104	199433
NZ 245618	A	19941026	NZ 245618	A	19930106	199442
JP 7010771	A	19950113	JP 9331074	A	19930106	199512
AU 664222	B	19951109	AU 9331045	A	19930105	199601
EP 603992	B1	19961009	EP 93300005	A	19930104	199645
DE 69305313	E	19961114	DE 605313	A	19930104	199651
			EP 93300005	A	19930104	
US 5591433	A	19970107	US 91719160	A	19910621	199708
			US 92994932	A	19921222	
			US 95405604	A	19950120	
ES 2095001	T3	19970201	EP 93300005	A	19930104	199712
CA 2086631	C	19981006	CA 2086631	A	19930104	199850
SG 52402	A1	19980928	SG 964016	A	19930104	199903
EP 603992	B2	20001206	EP 93300005	A	19930104	200064

Priority Applications (No Type Date): US 92994932 A 19921222; US 91719160 A 19910621; US 95405604 A 19950120

Cited Patents: BE 621398; EP 130163; GB 2178313; JP 56142211; 2.Jnl.Ref

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

EP 603992 A1 E 17 A61K-009/50

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

AU 9331045 A A61K-009/64

CA 2086631 A A61K-009/50

NZ 245618 A A61K-037/02

JP 7010771 A 11 A61K-038/00

AU 664222 B A61K-009/64 Previous Publ. patent AU 9331045

EP 603992 B1 E 15 A61K-009/50

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

DE 69305313 E A61K-009/50

Based on patent EP 603992

US 5591433 A 10 A61K-039/00

CIP of application US 91719160

Cont of application US 92994932

ES 2095001 T3 A61K-009/50

Based on patent EP 603992

CA 2086631 C A61K-009/50

SG 52402 A1 A61K-009/50

EP 603992 B2 E A61K-009/50

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

Abstract (Basic): EP 603992 A

An orally administered therapeutic protein (A) compsn. comprises a protein microencapsulated, in the absence of organic solvents, with a water based enteric coating.

Also claimed are: (1) a method for administering (A); and (2) a method for forming the therapeutic compsn. by forming an aq. solution contg. (A) and microencapsulating the protein with an aq. solution of an enteric coating with no organic solvents.

The enteric coating is a water based emulsion ethylacrylate methacrylic acid copolymer. (A) is selected from allergenic proteins digested fragments of allergenic proteins, viral vaccines, bacterial vaccines, protozoal vaccines, toxoids, glycoproteins, insulin, hGF, myelin basic protein, collagen S antigen, or TGF-beta. The compsn. further comprises a stabilising sugar e.g. lactose and water suspended aluminium salt.

USE/ADVANTAGE - (A) is administered orally and the coating protects it as it passes through the stomach. Upon reacting the small intestines, the basic pH of the intestinal juices dissolves the coating allowing the protein to be released. The stabilisation agent protects the protein from denaturation during encapsulation. (A), when released, induces an antigen specific response which has the specificity of the native molecule, hence it can be used as an allergen for treating human allergies.

Dwg. 0/11

Abstract (Equivalent): EP 603992 B

An orally administrable therapeutic composition comprising a therapeutic protein microencapsulated in the complete absence of organic solvents with a water based enteric coating.

(Dwg. 0/11)

Abstract (Equivalent): US 5591433 A

An orally administrable therapeutic composition comprises an immunogen microencapsulated in the complete absence of organic solvents with a water based enteric coating where the immunogen has an immunotherapeutic effect against an allergen in a warm blood animal.

Dwg. 0/11

Derwent Class: B04

International Patent Class (Main): A61K-009/50; A61K-009/64; A61K-037/02; A61K-038/00; A61K-039/00

International Patent Class (Additional): A61K-009/16; A61K-009/52; A61K-013/00; A61K-037/26; A61K-037/36; A61K-037/43; A61K-038/18; A61K-038/22; A61K-038/28; A61K-039/002; A61K-039/02; A61K-039/12; A61K-039/35; A61K-045/00; A61K-047/26; A61K-047/32; B01J-013/02; B01J-013/06